Rioprostil and ranitidine in the prevention of duodenal ulcer relapse.

One hundred and ninety duodenal ulcer patients who had relief of pain and endoscopically proven ulcer healing after a short treatment period are allocated at random to double-blind maintenance treatment with a synthetic dehydroprostaglandin-E1, rioprostil, 300 micrograms, or ranitidine, 150 mg, at bedtime for 6 months. Patients are monitored every two months and examined by endoscopy after six months of treatment, or more often if warranted. The cumulative relapse rate in the rioprostil group at six months is 32% (25/78) vs.

[Ranitidine inhibition of gastric secretion stimulated by pentagastrin. Results in 30 cases of duodenal ulcer].

The aim of this study was to investigate the effects of ranitidine on the pentagastrin stimulated gastric secretion (6 micrograms.kg.h) in 30 patients with duodenal ulcer.

[Inhibition by a 2-pyridyltetrahydrothiophene derivative (40749 RP) of gastric secretion stimulated by pentagastrin. Results in 30 duodenal ulcer patients].

The aim of this study was to investigate the effects of a new antisecretory compound (40749 RP) on the pentagastrin stimulated gastric secretion (6 micrograms.kg-1 b. w.

[Incomplete dissolution of calculi. Calcification, cholecystectomy, after treatment of biliary lithiasis with chenodeoxycholic acid].

Among 54 patients with radiolucent asymptomatic gallstones treated by chenodeoxycholic acid (CDCA), 32 failures were observed. In 15 cases the size of gallstones did not change. In 11 cases the size of gallstones decreased but dissolution was not complete.